PharmaShots Webinar: Mastering a Patient-Centric Approach for Treatment in Biopharma

Shaun Bagai, CEO of RenovoRx, shares insights on the company’s recent patents, ongoing clinical trials, and its upcoming presentation at SSO 2025.

This insightful session brought together industry leaders and patient advocates to discuss how patient-focused strategies are shaping the future of biopharma.

Featured Speakers:

T.J. Sharpe – Stage IV Melanoma Survivor & Patient Advocate
Shaun Bagai – CEO, RenovoRx
Leesa Gentry – CCO, RenovoRx

Key themes included:

Why patient-centricity is critical for innovation
Bridging the gap between patients and biopharma companies
Strategies to create better treatment outcomes & experiences

Watch the full discussion on Youtube

Recent News

TAMP-Mediated Gemcitabine Lowers Systemic Exposure vs IV Delivery in Locally Advanced Pancreatic Cancer

A pharmacokinetic sub-study of the phase 3 TIGeR-PaC trial shows TAMP-delivered gemcitabine significantly lowers systemic exposure compared to standard IV delivery in locally advanced pancreatic cancer.

RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth

RenovoRx today announced its financial results for the second quarter ended June 30, 2026, and provided shareholders with a business update highlighting continued commercial momentum and clinical progress.

RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer

RenovoRx is pleased to announce completion of enrollment in the Company’s Phase III TIGeR-PaC trial in locally advanced pancreatic cancer (LAPC).

RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors

RenovoRx today announced the first commercial clinical use of RenovoCath for drug-delivery in the treatment of a patient with sarcoma at the CARTI Cancer Center Little Rock (“CARTI”).